Workers from Google, Microsoft, Amazon, and Meta are paying $75,000 to be taller, a surgeon told GQ.
The Las Vegas surgeon can lengthen patients’ legs via a painful months-long process.
He breaks the thigh bones and inserts nails that are extended every day for three months.
A Las Vegas cosmetic surgeon who specializes in leg-lengthening procedures that can extend people’s height by 3 to 6 inches told GQ magazine that many of his patients are tech workers.
Kevin Debiparshad founded LimbplastX Institute in 2016, and the clinic’s business has boomed during the pandemic, he told GQ.
Here’s how it works: The doctor breaks the patients’ femurs, or thigh bones, and inserts metal nails into them that can be adjusted. The nails are extended a tiny bit every day for three months with a magnetic remote control, GQ reported.
It can take months to slowly lengthen the bones and for the legs to heal. One software engineer told GQ he spent the first three months after his surgery alone in his apartment and ordered delivery food during that time to go from 5-foot-6 to 5-foot-9.
The procedure costs between $70,000 and $150,000, depending on whether the patient wants to grow 3, 4, 5, or 6 inches, GQ said.
The common denominator of Debiparshad’s client base is that they’re wealthy, but they vary by profession: GQ reported that he’d treated CEOs, actors, and finance employees. And a bevy of high-earning tech workers — mostly men but some women — have come to him for the procedure.
“I joke that I could open a tech company,” Debiparshad told GQ. “I got, like, 20 software engineers doing this procedure right now who are here in Vegas. There was a girl yesterday from PayPal. I’ve got patients from Google, Amazon, Facebook, Microsoft. I’ve had multiple patients from Microsoft.”
The surgeon said he didn’t recommend the procedure for athletes since it could decrease their ability, and many of the patients GQ spoke to said they didn’t tell people they had the procedure done.
The stigma around plastic surgery for men has begun to fall away in recent years. Cosmetic procedures performed on men went up 325% from 1997 to 2015, according to the American Society for Aesthetic Plastic Surgery.
And within Silicon Valley, plastic surgery has increasingly become a way for male tech workers to reach their physical goals in recent years.
The Washington Post reported in January 2020 that men were turning to Botox, fillers, laser treatments, and techniques meant to stimulate collagen in an effort to get ahead in their careers.
Are you a tech worker who has undergone leg-lengthening surgery? Contact the author from a non-work email at kcanales@insider.com
Read the original article on Business Insider
Related Quotes
Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease. The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.
Shares of Nano-X Imaging (NASDAQ: NNOX), commonly called Nanox, soared on Wednesday after it revealed it's taken the next step toward commercializing its flagship medical device. As of 12:20 p.m. ET, Nanox stock was up 21%. Nanox had its initial public offering (IPO) in 2020, promising to disrupt the X-ray industry with its digital-3D imaging machines that will be cheaper for doctors to use.
Medicare beneficiaries will see their Part B premiums go down for the first time in more than a decade, President Biden said during a press conference on Tuesday. Monthly Part B premiums, which are currently set at $170.10 in 2022, will decline to $164.90 in 2023 – a $5.20 a month savings, or about $64 a year, according to the Centers for Medicare and Medicaid Services. The annual deductible for Part B will be $226, down $7 from $233 in 2022.
Ocugen Inc. (NASDAQ: OCGN) of Malvern entered into an exclusive license agreement Wednesday with Washington University in St. Louis for the rights to develop, manufacture and commercialize its proprietary, intranasally delivered Covid-19 vaccine in the United States, Europe, and Japan. It becomes the second Covid vaccine licensed by Ocugen, which continues to seek Food and Drug Administration approval for use of the other product, Covaxin, in the U.S. market. Under the financial terms of the deal, disclosed in documents filed with the Securities and Exchange commission, Ocugen will pay Washington University an initial license issuance fee of $1 million.
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
Data from Eisai and its partner Biogen are startling because their drug lecanemab slowed cognitive decline, and suggest that a theory that seemed all but disproved still has legs.
Cambridge, Massachusetts-based biotech Biogen and Japanese drug maker Eisai reported on Wednesday morning that their experimental Alzheimer's disease treatment had met the main goal of a late-stage clinical trial. The candidate, Lecanemab, reduced the pace of cognitive decline in patients diagnosed with early-stage disease by 27% over 18 months compared to those treated with a placebo. This result could be a major accomplishment for researchers who have been trying for decades to find a way to treat Alzheimer's. The medicine, before Biogen and Eisai started trying to develop it, was licensed from Sweden's BioArctic.
If so, it was probably for something like Berkshire Hathaway (NYSE: BRK.A), with an eye-popping price of $419,020 per share. Thankfully, there are much cheaper companies to buy, and some of them might even grow a bit faster than Warren Buffett's business. With its shares trading for around $13, having gained 139% in the past 12 months, Catalyst Pharmaceuticals (NASDAQ: CPRX) is a little-known biotech stock that's positioned to keep paying off for investors thanks to its progress in treating a rare neuromuscular disease called Lambert-Eaton myasthenic syndrome (LEMS).
For the 55 million people around the world who suffer from Alzheimer's and related dementias — not to mention their loved ones — Biogen's…
Parents have been forced to spend hours queuing outside vaccination centres in an effort to get their children polio boosters.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) announced new data from its Phase 1b trial evaluating the ability of its lead clinical candidate, mavorixafor, to increase the absolute neutrophil count (ANC) in chronic neutropenia (CN) patients as monotherapy or concurrently with injectable granulocyte colony-stimulating factor (G-CSF). People with CN have a lower number of neutrophils, a type of white blood cell, for more than three months. 100% of study participants (n=25) responded to treatment with a s
Crispr said Tuesday it will begin asking the FDA to approve its gene-editing blood diseases treatment in November, and CRSP stock jumped.
Americans will be paying less in monthly premiums for Medicare's Part B plan in 2023 — the first decrease in a decade. Medicare Enrollment: Out-of-Pocket Prescription Costs Included in the Inflation…
Story at a glance Drinking problems can affect physical and mental health. One study looked at long-term data on twins to understand how alcohol misuse in teen years could affect health later. The study finds a weak direct effect two decades later, with indirect effects potentially being a factor. A study published in Alcoholism: Clinical…
We're all over the pandemic and just want to go back to normal life, but COVID isn't done. In fact, cases are rising again across the United States and in several other countries thanks to Omicron which is considered the most contagious mutation yet. Furthermore, "one of the newest subvariants, called BA.2.75.2, can evade immune responses better than all earlier forms of Omicron," reports the Times. Eat This, Not That! Health spoke with experts who warn places to avoid in an effort to prevent ca
The White House held the Conference on Hunger, Nutrition, and Health — the first such conference in 50 years — on Sept. 28 to address hunger and diet-related diseases. The event comes amid a U.S….
Shares of Eli Lilly (NYSE: LLY) recently ticked higher in response to encouraging words from a Wall Street analyst who follows the pharmaceutical industry. Colin Bristow at UBS, an investment bank, thinks this is the most attractive pharma stock you can buy right now. Is Bristow right about Eli Lilly?
Vertex Pharmaceuticals (NASDAQ: VRTX), a commercial-stage biotech specializing in treatments for cystic fibrosis, saw its share price rise on Tuesday thanks to news about one of its pipeline programs.
The Biomedical Advanced Research and Development Authority (BARDA) has issued an $8.6 million contract to OraSure Technologies Inc (NASDAQ: OSUR) for developing a 2nd generation Ebola test on the OraQuick testing platform. The goal is for the 2nd generation test to have improved sensitivity, increased shelf life, new chemistry, and more automation compared to the de novo FDA-authorized test. Also see: FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests. OraSure's OraQuick E
British health officials on Wednesday warned that increased circulation of flu and a resurgence in COVID-19 could lead to a difficult winter that increases pressure on the already stretched National Health Service (NHS). Warnings over a possible "twindemic" of COVID-19 and flu have been issued each winter since the start of the coronavirus pandemic in early 2020, but COVID restrictions that limited social contact have meant flu levels stayed low. However, the government ended coronavirus restrictions earlier this year, meaning that social contact rates have returned to near pre-pandemic norms while immunity to flu is relatively low.